Du Pont's Neurolite approved by FDA

Article

Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a

Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a technetium-labeled agent. DuPont Merck, of North Billerica, MA, plans to begin shipping Neurolitein January. The product is indicated for brain perfusion studiesin stroke patients (SCAN 9/14/94).

Related Videos
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Emerging Innovations in Molecular Imaging
Related Content
© 2023 MJH Life Sciences

All rights reserved.